Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16099938 | 0.84 | PRCP (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL30015849 | 0.76 | CARM1 (0.34) | RAD52 | |
| SCHEMBL22406255 | 0.76 | TRPV1 (0.31) | TRPV1 | |
| SCHEMBL28958495 | 0.75 | TRPV1 (0.31) | TRPV1 | |
| SCHEMBL16101825 | 0.72 | JAK1 (0.38) | — | |
| SCHEMBL22447807 | 0.71 | — | — | |
| SCHEMBL28881754 | 0.70 | PRMT3 (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL16100522 | 0.70 | TRPV1 (0.31) | TRPV1 | |
| SCHEMBL28881755 | 0.69 | — | — | |
| Trifluoroacetic Acid SCHEMBL19348062 | 0.67 | TPSAB1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265400-B | Arginine methyltransferase inhibitors and uses thereof | EPIZYME股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2970132-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200289469-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-10632103-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20180289671-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-10-11 | — | — | US | disclosed |
| US-10081603-B2 | Arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9724332-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598374-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160184267-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2016-06-30 | — | — | US | disclosed |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
| US-9120757-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081603-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20200289469-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-10632103-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20160184267-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
| US-20180289671-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TRPV1 4841/4885RAD52 3590/4885CPB2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.